Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AdvaMed on price transparency

This article was originally published in The Gray Sheet

Executive Summary

Healthcare value measures should incorporate clinical outcomes of entire episodes of care and should not be based solely on cost or "artificially fixed time periods," according to a 1policy position passed by AdvaMed's board Dec. 14. The trade group adds that measures should risk-adjust for patient complexity, place minimal burdens on providers, and ensure continued access to the full array of medical technologies. The position follows an August order by President Bush requiring four government agencies to begin transparency initiatives in January that will make price and quality of care data publicly available (2"The Gray Sheet" Aug. 28, 2006, p. 16)...

You may also be interested in...

Device Firms Would Have To Report Sales Prices To CMS Under Senate Bill

A bill introduced Oct. 23 in the Senate would require device makers seeking Medicare reimbursement to report to CMS the prices they negotiate with hospitals and other buyers for all implantable medical devices

Administration Unveils Transparency Initiatives; Private Sector Follows Suit

The Bush Administration took several steps last week in its agenda for improving public access to price and quality information on healthcare procedures, and some private insurers have followed suit

Belgium Aims To Drive Biologic Competition Through Tendering

New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts